AU2009333809A1 - Methods for increasing endogenous plasmalogen levels - Google Patents

Methods for increasing endogenous plasmalogen levels Download PDF

Info

Publication number
AU2009333809A1
AU2009333809A1 AU2009333809A AU2009333809A AU2009333809A1 AU 2009333809 A1 AU2009333809 A1 AU 2009333809A1 AU 2009333809 A AU2009333809 A AU 2009333809A AU 2009333809 A AU2009333809 A AU 2009333809A AU 2009333809 A1 AU2009333809 A1 AU 2009333809A1
Authority
AU
Australia
Prior art keywords
animal
lcpufas
administered
amounts
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009333809A
Other languages
English (en)
Inventor
Jean-Baptiste Bezelgues
Cristina Cruz-Hernandez
Frederic Destaillats
Fabiola Dionisi
Wedell Ray Guffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of AU2009333809A1 publication Critical patent/AU2009333809A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2009333809A 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels Abandoned AU2009333809A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20417009P 2009-01-02 2009-01-02
US61/204,170 2009-01-02
PCT/US2009/006749 WO2010077358A1 (en) 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels

Publications (1)

Publication Number Publication Date
AU2009333809A1 true AU2009333809A1 (en) 2011-07-14

Family

ID=42310073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009333809A Abandoned AU2009333809A1 (en) 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels

Country Status (10)

Country Link
US (1) US20110275600A1 (enExample)
EP (1) EP2373161A4 (enExample)
JP (1) JP2012514597A (enExample)
CN (1) CN102271502A (enExample)
AU (1) AU2009333809A1 (enExample)
CA (1) CA2747582A1 (enExample)
MX (1) MX2011007188A (enExample)
RU (1) RU2011132386A (enExample)
WO (1) WO2010077358A1 (enExample)
ZA (1) ZA201105665B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102413822A (zh) * 2009-03-04 2012-04-11 雀巢产品技术援助有限公司 提高哺乳动物中内源性缩醛磷脂水平的方法
JP6025568B2 (ja) * 2010-12-28 2016-11-16 株式会社藤野ブレインリサーチ 認知症を血液サンプルで判定するための検査方法
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型ｄｈａ増加剤
JP7704407B2 (ja) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 がん治療用組成物
JP2023108631A (ja) * 2022-01-26 2023-08-07 大道 藤本 ドッグフード

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20080044487A1 (en) * 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
CN101675337A (zh) * 2007-04-13 2010-03-17 菲诺梅诺米发现公司 用于缩醛磷脂缺乏介导的衰老疾病的诊断和危险评估的方法

Also Published As

Publication number Publication date
JP2012514597A (ja) 2012-06-28
ZA201105665B (en) 2013-01-30
CN102271502A (zh) 2011-12-07
RU2011132386A (ru) 2013-02-10
EP2373161A1 (en) 2011-10-12
WO2010077358A1 (en) 2010-07-08
US20110275600A1 (en) 2011-11-10
CA2747582A1 (en) 2010-07-08
MX2011007188A (es) 2011-09-01
EP2373161A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
Calder et al. Polyunsaturated fatty acids, inflammation and immunity
AU2016202685B2 (en) Compositions and methods for enhancing cognitive function
EP1296670B1 (en) Therapeutic combinations of fatty acids
CA2316298C (en) Fat blend
US20110275600A1 (en) Methods for increasing endogenous plasmalogen levels
EP3310349A1 (en) Compositions and methods for enhancing neurogenesis in animals
CA2963350A1 (en) Compositions and methods for enhancing mobility or activity or treating frailty
RU2413427C2 (ru) Способы и композиция для улучшения когнитивной функции
WO2014022816A2 (en) Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
AU2017440239B2 (en) Compositions comprising omega-3 polyunsaturated and medium chain fatty acids
JPH04501114A (ja) トリグリセリド，該トリグリセリドを含んでなる栄養組成物、および栄養物用の栄養組成物の使用
AU2011349718B2 (en) Methods and compositions for preventing and treating osteoarthritis
US20040132819A1 (en) Appetite control method
JP2025531817A (ja) 動物に健康上の効果を提供するための南洋サバ油を利用した組成物及び方法
Goffin et al. Effects of matrix on plasma levels of EPA and DHA in dogs
EP3076978A1 (en) Serine glycerophospholipid preparation and method for treatment of seizures
JP2018177734A (ja) 脂質吸収促進剤
WO2017153841A1 (en) Phospholipid preparations for the improvement of brain plasticity
Loes Fatty acids: time to change your oil!
CN107970232A (zh) 含n-3系不饱和脂肪酸的组合物、及n-3系不饱和脂肪酸在该组合物的制造中的应用
HK1050486B (en) Therapeutic combinations of fatty acids
HK1033541B (en) Fat blend

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application